John Lambert
Consultant & Honorary Professor Queen's University Belfast
John joined the Dana-Farber Cancer Institute, Harvard Medical School, Boston, as the second scientist recruited in 1981 to work on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins for cancer therapy. He later held several leadership roles at ImmunoGen, including Executive Vice President of Research and Chief Scientific Officer (2008- 2015), and Distinguished Research Fellow until his retirement in 2017. During his tenure at ImmunoGen, the team invented and developed the ADC technology behind KADCYLA® and ELAHERE® and discovered the anti-CD38 antibody that became the SARCLISA®.
John holds a Ph.D. in Biochemistry from the University of Cambridge and has authored over 125 peer-reviewed scientific publications. He is a Fellow of the American Institute for Medical and Biological Engineering, and an Honorary Professorship at The Queen’s University Belfast.
Seminars
Are you new to the ADC field? If so, join our ADC 101 day to get your ADC knowledge up to scratch ahead of the scientific programme days.
Targeted towards those new to ADCs, this seminar day will provide you with the critical knowledge gained over years of research and failed clinical trials that culminated in the presently approved ADCs and booming innovation in the field.
Led by a long-standing expert and KOL in the field, join this one-stop-shop of ADC learning to establish a
core understanding of the essential elements in ADC discovery and early development.
- Debating the optimal chemical and biological properties of next-generation payload and linker combinations
- Exploring the novelty of dual-payload ADCs and their potential to overcome resistance mechanisms associated with traditional ADCs
- Assessing the potential of novel ‘XDC’ candidates to expand therapeutic applications and unlock untapped opportunities within an increasingly crowded ADC landscape
